Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.40 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008512 | 0.77 | UGT2B7 (0.47) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9852879 | 0.71 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL1663204 | 0.68 | UGT2B7 (0.57) | AOC3CYP2D6UGT2B7ADRA2AADRA2B | |
| SCHEMBL5515413 | 0.67 | UGT2B7 (0.52) | AOC3CYP2D6UGT2B7ADRA2AADRA2B | |
| SCHEMBL19986352 | 0.66 | SLC6A3 (0.51) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1753651 | 0.66 | UGT2B7 (0.59) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9005796 | 0.64 | UGT2B7 (0.47) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7434128 | 0.64 | UGT2B7 (0.57) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2650436 | 0.64 | UGT2B7 (0.52) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7676445 | 0.64 | UGT2B7 (0.56) | AOC3SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | AOC3 1192/4885SLC6A2 1965/4885SLC6A4 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.